Document:

<PAGE>

                                                                   EXHIBIT 10.94
                             SUBLICENSE AGREEMENT
                                    OF THE
                     DIACLONE MONOCLONAL ANTIBODY LICENSE

     This SUBLICENSE AGREEMENT OF THE DIACLONE MONOCLONAL ANTIBODY LICENSE
("Agreement"), dated as of August 31, 2001 ("Effective Date") is entered into by
  ---------                                  --------------
and between Baxter Healthcare Corporation, a Delaware corporation having its
principal place of business at One Baxter Parkway, Deerfield, Illinois 60015
("Baxter"), and Nexell of California, Inc., a Delaware corporation having its
  ------
principal place of business at Nine Parker, Irvine, California 92618 ("Nexell").
                                                                       ------

                                   RECITALS

     WHEREAS, Nexell entered into a certain Monoclonal Antibody License
Agreement, dated as of September 30, 1999 (the "License Agreement"), annexed as
                                                -----------------
Exhibit A hereto, under which Diaclone SA ("Licensor") granted to Nexell certain
                                            --------
rights to the Licensed Intellectual Property (as hereafter defined).

     WHEREAS, Nexell desires to sublicense to Baxter certain rights under the
License Agreement in order to enable Baxter to perform its sale, marketing and
distribution obligations under that certain Distribution and License Agreement
by and between Nexell and Baxter dated as of August 31, 2001 (the "Distribution
                                                                   ------------
and License Agreement").
---------------------

                                   AGREEMENT

     NOW THEREFORE, for good and valuable consideration, including the promises
contained herein, the parties do hereby agree to be bound as follows:

1.   Definitions

     1.1  Terms Defined in the License Agreement. Capitalized terms not
          --------------------------------------
          otherwise defined herein shall have the meanings given them in the
          License Agreement.

     1.2  As used herein, the following terms shall have the specified meaning:

          (a)  "Licensed Intellectual Property" shall mean the intellectual
                ------------------------------
               property defined in the License Agreement under Sections 1(b),
               1(c), 1(f), 1(h) and 1(i).

          (b)  "Non-Compete Agreement" shall mean the Non-Competition and
                ---------------------
               Confidentiality Agreement, by and among Baxter, Nexell, and
               VIMRx Pharmaceuticals Inc., dated as of December 18, 1997,
                    as amended.

          (c)  "Products" shall have the meaning ascribed to it in the
                --------
               Distribution and License Agreement.
<PAGE>

          (d)  "Product Categories" shall have the meaning ascribed to it in the
                ------------------
               Distribution and License Agreement.

          (e)  "Supply Agreement" shall mean the Supply Agreement by and between
                ----------------
               Baxter and Nexell dated as of August 31, 2001.

2.   Payment.

     Baxter agrees to pay, perform, discharge or otherwise satisfy, or cause to
be paid, performed, discharged or otherwise satisfied the obligations under the
License Agreement arising on or after the date hereof with respect to any
Products sold by Baxter by transmitting any and all payments and reports
directly to Licensor, with simultaneous written notice thereof to Nexell.

3.   License Grant by Nexell to Baxter

     Nexell hereby grants to Baxter: (i) an exclusive (even as to Nexell),
worldwide license under the Licensed Intellectual Property to market and sell
the Products, and any components thereof; (ii) an exclusive (except as to
Nexell), worldwide license under the Licensed Intellectual Property to make,
have made and import the Products, and any components thereof; (iii) an
exclusive (even as to Nexell) worldwide license under the Licensed Intellectual
Property to use the Products and components solely for the distribution purpose
set forth in Section 5 of the Distribution and License Agreement; and (iv) an
exclusive (except as to Nexell), worldwide license under the Licensed
Intellectual Property for internal research and development purposes (including
clinical trials) to improve Products for Ex Vivo Cell Processing (as such term
is defined in the Non-Compete Agreement) (the "License"). The foregoing license
                                               -------
rights shall not include the right for Baxter to use the Licensed Intellectual
Property to practice Ex Vivo Cell Processing commercially. Either party shall
have the right to sublicense its rights described in this Section 3, provided
such party has obtained the other party's prior written consent (such consent
not to be unreasonably withheld or delayed) and any such sublicensee agrees to
be bound by the terms and conditions of this Agreement and the Non-Compete
Agreement (the terms of which shall be binding upon any sublicensee in the same
manner and to the same extent such terms bind the applicable licensor).

4.   Notification of Payments and Reports

     Each party shall notify the other party of any payment, royalty payment,
FDA marketing approval and first commercial sale in each country where such sale
is made and shall provide the other party with copies of any payment or report
transmitted to Licensor concurrent with the transmittal of same to Licensor.

5.   Nexell's Rights to Avoid Termination of License Agreement; Termination;
     Non-Modification; Exclusivity

     5.1  Baxter shall provide Nexell with written notice within three (3)
          business days of the occurrence of any of the following:

          (a)  Failure to meet its royalty payment obligations under the License
               Agreement;
<PAGE>

          (b)  Baxter's material breach of any other obligation under the
               License Agreement;

          (c)  Receipt of any notification or other communication relating or
               otherwise referring to Baxter's alleged breach of its
               responsibilities under the License Agreement or threatening
               termination of the License Agreement.

     5.2  After receipt of notice under Section 5.1 above, or, in the event that
          Nexell, in good faith, after consultation with Baxter, reasonably
          believes that the License Agreement will be terminated absent action
          by Nexell, Nexell may, at its option, take such actions it considers
          to be reasonably necessary in order to avoid such termination. To the
          extent Nexell advances payments on Baxter's behalf, such payment shall
          be considered a loan to Baxter. Interest on the amount advanced shall
          accrue and be payable from the date advanced at a rate of 1% per month
          (or the highest rate allowed by law, if lower) compounded annually,
          until fully paid (including full payment of such interest).

     5.3  Final Notice to Cure. In the event Nexell exercises its rights under
          --------------------
          Section 5.2 above, Nexell shall be entitled to terminate this
          Agreement, provided, Nexell serves Baxter with thirty (30) days prior
          notice of its intention to terminate, and gives Baxter the opportunity
          to cure the breach which necessitated Nexell's action under Section
          5.2 above, including the payment of any fees, plus interest, due and
          owing to Nexell, and/or a reimbursement of Nexell's costs and expenses
          incurred by Nexell in exercising its rights under Section 5.2 above.

     5.4  Early Termination. Nexell may terminate this Agreement if a final,
          -----------------
          non-appealable decision is rendered by an arbitrator or a court of
          competent jurisdiction holding that Baxter has materially breached its
          obligations under Section 2 of the Non-Compete Agreement after having
          been given at least 180 days notice of such breach by Nexell. In
          addition, upon the termination of the Distribution and License
          Agreement in accordance with its terms, this Agreement shall
          automatically terminate.

     5.5  Termination for Baxter Bankruptcy. This Agreement and the license
          ---------------------------------
          granted hereunder shall automatically terminate, without further
          action of any kind by Nexell, upon bankruptcy, insolvency, assignment
          for the benefit of creditors or other act of insolvency by, or against
          Baxter.

     5.6  Non-Modification. Except as expressly permitted herein, neither party
          ----------------
          shall take any action to amend, extend, terminate or otherwise modify
          the terms and conditions of, or the rights and obligations of the
          parties to, the License Agreement without the prior written consent of
          the other party.

     5.7  Exclusivity. To the extent that Baxter becomes a non-exclusive
          -----------
          marketing, sales and distribution entity with regard to any Products
          Category(ies) in specified countries under the Distribution and
          License Agreement, Baxter shall similarly
<PAGE>

          convert into a non-exclusive marketing, sales and distribution entity
          for the same Product Category(ies) in the same countries pursuant to
          this Agreement.

6.   Enforcement of Licensed Intellectual Property Rights. Baxter and Nexell
     shall each, promptly, but in no event no later than thirty (30) days after
     receipt of notice thereof, notify the other of any patent nullity actions,
     oppositions, reexaminations, any declaratory judgment actions or any
     alleged or threatened infringement of patents or patent applications or
     misappropriation or violation of any Licensed Intellectual Property, or if
     Baxter or Nexell, or any of their respective Affiliates, shall be named as
     a defendant in a legal proceeding by a third party alleging infringement,
     misappropriation or violation of a patent or other intellectual property
     right as a result of the manufacture, production, use, distribution or sale
     of any Product or of any other information or notification regarding the
     Licensed Intellectual Property.

     6.1  Baxter and Nexell shall cooperate in any action taken by a third party
          solely involving a nullity action, opposition, reexamination or any
          other action taken by such third party alleging the invalidity or
          unenforceability of any Licensed Intellectual Property. Both parties
          agree to share equally in the cost of the defense of such Licensed
          Intellectual Property.

     6.2  Baxter shall have the first right to respond to, defend or prosecute
          any actions taken to defend any alleged or threatened infringement,
          misappropriation or any other violation by a third party of Baxter's
          rights under the license granted in Section 3 of this Agreement. It is
          understood that such action may include defending against a nullity
          action or similar action or causes of action taken by such third party
          in such proceedings or actions. Nexell agrees to cooperate with Baxter
          and its legal counsel, join in suits or actions that may be brought by
          Baxter, at Baxter's request, allow itself to be named as a party, at
          Baxter's request, and be available at Baxter's reasonable request to
          be an expert witness or otherwise to assist in such proceedings. If
          Baxter elects to respond to, defend, prosecute or settle any such
          actions, challenges, infringements, misappropriations or proceedings
          by a third party alleging infringement, misappropriation or violation
          of Baxter's rights as described above then: (i) Baxter shall bear all
          legal fees and other costs and expenses associated with such response
          or defense, including those incurred by Nexell at Baxter's request;
          and (ii) Baxter shall keep all amounts recovered from third parties in
          connection with such response or defense. Furthermore, Baxter shall
          have the right to license such Licensed Intellectual Property in
          connection with any settlement of any such claim, with the prior
          written consent of Nexell (such consent not to be unreasonably
          withheld or delayed). Baxter shall have six (6) months to elect to
          respond to, defend or prosecute any such allegations of infringement,
          misappropriation or violation of rights. If Baxter declines to respond
          to, defend or prosecute any such action within such six (6) month
          period, then Nexell shall have the right to elect to bring any
          necessary action to defend or prosecute any such allegations of
          infringement, misappropriation or violation of rights. Notwithstanding
          anything to the contrary set forth in this Section 6.2, it is
          understood that nothing contained in this Section 6.2 shall limit,
          impose any additional obligation on or otherwise alter Nexell's
<PAGE>

          obligation to indemnify Baxter under the Distribution and License
          Agreement or this Agreement.

     6.3  For any such actions against a third party alleging any infringement,
          misappropriation or violation of rights that are not included under
          the rights granted to Baxter under the license granted in Section 3 of
          this Agreement, Nexell shall have six (6) months to elect to respond
          to, defend or prosecute any such allegations of infringement,
          misappropriation or violation of rights. If Nexell declines to make
          any such election within such six (6) month period, then Nexell hereby
          grants Baxter automatically the exclusive right to elect to bring any
          necessary action to defend or prosecute any such allegations of
          infringement, misappropriation or violation of rights. If Baxter
          elects to do so, then Nexell's license grant to Baxter under the
          license granted in Section 3 of this Agreement shall be deemed to be
          amended to include an exclusive license to take whatever actions are
          necessary for Baxter (and solely for the purpose of the foregoing) to
          respond to, defend or prosecute any such actions to enforce such
          rights, including the right to seek past damages. In connection
          therewith, Nexell agrees to cooperate with Baxter and its legal
          counsel, join in suits or actions that may be brought by Baxter, at
          Baxter's request, allow itself to be named as a party, at Baxter's
          request, and be available at Baxter's reasonable request to be an
          expert witness or otherwise to assist in such proceedings. Baxter
          shall bear all legal fees and other costs and expenses associated with
          such response or defense, including those incurred by Nexell at
          Baxter's request, and Baxter shall keep all amounts recovered from
          third parties in connection with such response or defense.
          Furthermore, Baxter shall have the right to license such Licensed
          Intellectual Property in connection with any settlement of any such
          claim, with the prior written consent of Nexell (such consent not to
          be unreasonably withheld or delayed). Notwithstanding anything to the
          contrary set forth in this Section 6.3, it is understood that nothing
          contained in this Section 6.3 shall limit, impose any additional
          obligation on or otherwise alter Nexell's obligation to indemnify
          Baxter under the Distribution and License Agreement or this Agreement.

7.   Indemnification

     7.1  Indemnification by Nexell. Nexell shall defend, indemnify and hold
          -------------------------
          Baxter and its Affiliates harmless from and against any and all
          claims, suits and expenses, including reasonable attorney expenses,
          arising out of or relating to (i) Nexell's breach of this Agreement;
          and (ii) Nexell's breach of the License Agreement.

     7.2  Indemnification by Baxter. Baxter shall defend, indemnify and hold
          -------------------------
          Nexell and its Affiliates harmless from and against any and all
          claims, suits and expenses, including reasonable attorney expenses,
          arising out of or relating to (i) Baxter's breach of this Agreement;
          and (ii) any claim for property damage, personal injury or death
          arising out of the manufacture, use, sale or other disposition of any
          products that use the Licensed Intellectual Property by Baxter, its
          Affiliates or sublicensees; provided, however, that in the event that
                                      --------  -------
          any product is a Product,
<PAGE>

          the indemnification provisions in the Distribution and License
          Agreement shall exclusively govern any claim.

8.   Dispute Resolution

     8.1  Provisional Remedies. The procedures specified in this Section 8 shall
          --------------------
          be the sole and exclusive procedures for the resolution of disputes
          between the parties arising out of or relating to this Agreement;
          provided, however, that a party, without prejudice to these
          --------  -------
          procedures, may seek a preliminary injunction or other provisional
          relief if, in its sole judgment, such action is deemed necessary to
          avoid irreparable damage or to preserve the status quo. During such
          action, the parties will continue to participate in good faith in the
          procedures specified in this Section 8.

     8.2  Negotiations Between Executives. The parties will attempt in good
          -------------------------------
          faith to resolve any claim or controversy arising out of or relating
          to the execution, interpretation or performance of this Agreement
          (including the validity, scope and enforceability of the provisions
          contained in this Section 8) promptly by negotiations between
          executives who have authority to settle the controversy and who are at
          a higher level of management than the persons with direct
          responsibility for the administration of this Agreement.

     8.3  Arbitration. In the event that any dispute arising out of or relating
          -----------
          to this Agreement or its breach, termination or validity has not been
          resolved after good faith negotiation pursuant to the procedures of
          Section 8.2, such dispute shall upon written notice by either party to
          the other, be finally settled by arbitration administered by the
          Center for Public Resources in accordance with the provisions of its
          Commercial Arbitration Rules and the United Stated Federal Arbitration
          Act, as modified below:

          (a)  The arbitration shall be heard by a panel of three (3)
               independent and impartial arbitrators, all of whom shall be
               selected from a list of neutral arbitrators supplied by the
               Center for Public Resources. From such list, each of Baxter and
               Nexell shall select one (1) arbitrator, and the arbitrators so
               selected shall select a third. The panel shall designate one (1)
               among them to serve as chair.

          (b)  The arbitration proceedings shall be conducted in Los Angeles
               County or Orange County in the State of California.

          (c)  Any party may seek interim or provisional remedies under the
               Federal Rules of Civil Procedure and the United States Federal
               Arbitration Act as necessary to protect the rights or property of
               the party pending the decision of the arbitrators.

          (d)  The parties shall allow and participate in limited discovery for
               the production of documents and taking of depositions, which
               shall be conducted in accordance with the Commercial Arbitration
               Rules of the
<PAGE>

               Center for Public Resources. All discovery shall be completed
               within sixty (60) days following the filing of the answer or
               other responsive pleading. Unresolved discovery disputes shall be
               brought to the attention of the chair of the arbitration panel
               and may be disposed of by the chair.

          (e)  Each party shall have up to fifty (50) hours to present evidence
               and argument in a hearing before the panel of arbitrators,
               provided that the chair of the panel of arbitrators may establish
               such longer times for presentations as the chair deems
               appropriate.

          (f)  The arbitration award shall be rendered by the arbitrators within
               fifteen (15) business days after conclusion of the hearing of the
               matter, shall be in writing and shall specify the factual and
               legal basis for the award. Judgment thereon may be entered in any
               court having jurisdiction thereof.

          (g)  The arbitrators are empowered to order money damages in
               compensation for a party's actual damages, specific performance
               or other appropriate relief to cure a breach; provided, however,
                                                             --------  -------
               that the arbitrators will have no authority to award special,
               punitive or exemplary damages, or other money damages that are
               not measured by the prevailing party's actual damages.

     8.4  Performance During Dispute. Each party is required to continue to
          --------------------------
          perform its obligations under this Agreement pending final resolution
          of any dispute arising out of or relating to this Agreement, unless to
          do so would be commercially impossible or impractical under the
          circumstances.

9.   General

     9.1  Provisions Contrary to Law/Severability. In performing this Agreement,
          ---------------------------------------
          the parties hereto shall comply with all applicable laws. Nothing in
          this Agreement shall be construed so as to require the violation of
          any law, and wherever there is a conflict between any provision of
          this Agreement and any applicable law, the applicable law shall
          prevail. In the event any provision of this Agreement conflicts with
          any applicable law or is otherwise determined by an arbitrator or
          court having valid jurisdiction thereof to be unenforceable, the
          affected provision of this Agreement shall be deemed to have been
          modified to the extent necessary so as not to conflict with the
          applicable law or to be unenforceable or, if such modification is not
          possible, such provision shall be deemed to have been deleted
          herefrom, without affecting, impairing or invalidating the remaining
          provisions of this Agreement.

     9.2  Foreign Government Approval or Registration. If this Agreement or any
          -------------------------------------------
          associated transaction is required by the law of any nation to be
          either approved or registered with any governmental authority, or any
          agency or political subdivision thereof, Baxter shall assume all legal
          obligations to do so. In connection
<PAGE>

          therewith, Nexell shall cooperate and assist with all reasonable
          requests by Baxter.

     9.3  Export Control. Each party shall observe all applicable United States
          --------------
          and foreign laws with respect to the transfer of Products and related
          technical data to foreign nations, countries and other sovereign
          states.

     9.4  Notices. All notices required under this Agreement shall be in
          -------
          writing, and all such notices and other written communications
          (including product orders and invoices) shall be delivered either by
          hand, by a nationally recognized overnight delivery service (with
          delivery charges prepaid), by first class, registered or certified
          United States mail (postage prepaid), or by facsimile transmission
          (provided that in the case of facsimile transmission, a confirmation
          copy of the notice shall be delivered by hand, by a nationally
          recognized overnight delivery service (with charges prepaid), or by
          first class, registered or certified United States mail (postage
          prepaid) within two (2) days of facsimile transmission), addressed to
          each party as follows:

          If to Baxter, such notices and any other written communications shall
          be delivered to:

          Baxter Healthcare Corporation
          Oncology
          One Baxter Parkway
          Deerfield, Illinois 60015
          Attention: Cindy Collins - General Manager
          Telecopy:  (847) 948-4684

          With copies to:

          Baxter Healthcare Corporation
          P.O. Box 15210
          Irvine, California 92623-5210
          Attention: Michael Schiffer, Esq. - Chief Patent Counsel
          Telecopy:  (949) 474-6330

          and

          Baxter Healthcare Corporation
          Baxter Biosciences
          One Baxter Parkway
          Deerfield, Illinois 60015
          Attention: President - Venture Management
          Telecopy:  (847) 940-6271

          If to Nexell, such notices and any other written communications shall
          be delivered to:
<PAGE>

          Nexell of California, Inc.
          Nine Parker
          Irvine, California 92618
          Attention: President and CEO
          Telecopy:  (949) 470-6645

          With copies to:

          Bryan Cave LLP
          700 Thirteenth Street, N.W.
          Washington, D.C. 20005
          Attention: Eric F. Stoer, Esq.
          Telecopy:  (202) 508-6200

          and  to:

          Nexell Therapeutics Inc.
          Nine Parker
          Irvine, California 92618
          Attention: Chairman
          Telecopy:  (949) 470-6645

          or such other address as any such party may designate in writing and
          delivered to the other party hereto pursuant to this Section 9.4. All
          such notices or other written communications shall be deemed to have
          been received by the addressee if delivered by: hand or by a
          nationally recognized overnight delivery service (with delivery
          charges prepaid) at the time of delivery; by first class, registered
          or certified United States mail (postage prepaid), three (3) business
          days after delivery thereof to the United States Postal Service; or by
          facsimile transmission, at the time of transmission.

     9.5  Force Majeure. Neither party to this Agreement shall be liable for
          -------------
          delay or failure in the performance of any of its obligations
          hereunder if such delay or failure is due to causes beyond its
          reasonable control, including acts of God, fires, earthquakes, strikes
          and labor disputes, acts of war, civil unrest or intervention of any
          governmental authority, but any such delay or failure shall be
          remedied by such party as soon as is reasonably possible. A party's
          lack of financial resources to effect its performance hereunder shall
          not be considered a force majeure event.

     9.6  Limitation of Liability. IN NO EVENT, WHETHER AS A RESULT OF BREACH OF
          -----------------------
          CONTRACT, TORT LIABILITY (INCLUDING NEGLIGENCE), OR OTHERWISE, SHALL
          EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY SPECIAL, PUNITIVE,
          EXEMPLARY OR LIQUIDATED DAMAGES.
<PAGE>

     9.7  Use of Names. Neither party shall be permitted to use the name of the
          ------------
          other in any promotional materials or advertising related to the
          Products without the prior written consent of the other or as
          permitted by the Distribution and License Agreement or Supply
          Agreement.

     9.8  Assignment. Nexell shall not assign its rights or obligations under
          ----------
          this Agreement to any party during the term of the Distribution and
          License Agreement and Supply Agreement without the prior written
          consent of Baxter. Notwithstanding the foregoing, and subject to the
          terms of the Stockholders Agreement, Nexell may assign its rights
          under this Agreement in the event of a sale, merger or other business
          combination of Nexell with or into another business, provided that
          Nexell obtains the advance written consent of Licensor. Baxter may
          assign its rights and obligations hereunder to any party without prior
          notice to or consent of Nexell. Subject to the foregoing, this
          Agreement shall inure to the benefit of and be binding on the parties'
          permitted successors and assigns.

     9.9  Waivers and Modifications. The failure of any party to insist on the
          -------------------------
          performance of any obligation hereunder shall not be deemed to be a
          waiver of such obligation. Waiver of any breach of any provision
          hereof shall not be deemed to be a waiver of any other breach of such
          provision or any other provision. No waiver, modification, release or
          amendment of any obligation under or provision of this Agreement shall
          be valid or effective unless in writing signed by the other party to
          be bound by such waiver, modification, release or amendment.

     9.10 Choice of Law and Jurisdiction. This Agreement shall be governed by
          -------------------------------
          and construed in accordance with the internal laws of the State of
          Delaware, without application of conflicts of law principles, and,
          subject to Section 9.9, each party hereby submits to the jurisdiction
          and venue of any state or federal court in the State of Delaware. To
          the extent permissible by law, each of the parties hereby waives,
          releases and agrees not to assert, and agrees to cause its Affiliates
          to waive, release and not assert, any rights such party or its
          Affiliates may have under any foreign law or regulation that would be
          inconsistent with the terms of this Agreement as governed by Delaware
          law.

     9.11 Independent Parties. By virtue of this Agreement, neither party
          -------------------
          constitutes the other as its agent (except as may otherwise be
          expressly provided herein), partner, joint venturer, or legal
          representative and neither party has express or implied authority to
          bind the other in any manner whatsoever.

     9.12 Entire Agreement. This Agreement and the Non-Compete Agreement,
          ----------------
          together with the License Agreement and the Exhibits and Schedules
          annexed thereto, and the Asset Purchase Agreement dated as of August
          3, 2001, by and among Baxter, Nexell and Nexell Therapeutics Inc., and
          all agreements contemplated thereby (including the agreements noted on
          Schedule 5.15 thereof as continuing in effect), constitute the entire
          agreement between the parties as to the subject matter hereof, and all
          prior negotiations, representations, agreements and understandings are

<PAGE>

          merged into, extinguished by and completely expressed by this
          Agreement and the other agreements referred to above.

     9.13 Counterparts. This Agreement may be executed in any number of
          ------------
          counterparts with the same effect as if all parties had signed the
          same document. All such counterparts shall be deemed an original,
          shall be construed together, and shall constitute one and the same
          instrument.

     9.14 Rules of Construction. In this Agreement, unless a clear contrary
          ---------------------
          intention appears:

          (a)  The singular number includes the plural number and vice versa;

          (b)  Reference to any party includes such party's permitted successors
               and assigns;

          (c)  Reference to any gender includes the other gender;

          (d)  Reference to any Section, Exhibit or Schedule means such section
               of this Agreement, exhibit to this Agreement or schedule to this
               Agreement, as the case may be, and references in any section or
               definition to any clause means such clause of such section or
               definition;

          (e)  "Herein," "hereunder," "hereof," "hereto," and words of similar
               import shall be deemed references to this Agreement as a whole
               and not to any particular section or other provision of this
               Agreement;

          (f)  "Including" (and with the correlative meaning "include") means
               including without limiting the generality of any description
               preceding such term;

          (g)  Relative to the determination of any period of time, "from" means
               "from and including," "to" means "to but excluding" and "through"
               means "through and including";

          (h)  Reference to any law (including statutes and ordinances) means
               such law as amended, modified, codified or reenacted, in whole or
               in part, and in effect from time to time, including rules and
               regulations promulgated thereunder;

          (i)  Accounting terms used herein shall have the meanings historically
               attributed to them by Baxter Inc., a Delaware corporation, and
               its subsidiaries prior to the date hereof;

          (j)  In the event of any conflict between any of the provisions of the
               body of this Agreement and any exhibit or schedule hereto, the
               provisions of the body of this Agreement shall control;
<PAGE>

          (k)  The headings contained in this Agreement have been inserted for
               convenience of reference only, and are not to be used in
               construing this Agreement; and

          (l)  Any rule of construction or interpretation which might otherwise
               require this Agreement to be construed or interpreted against
               either party shall not apply to any construction or
               interpretation hereof.

             [THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]
<PAGE>

     IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the
date first set forth above.

                                         BAXTER HEALTHCARE CORPORATION

                                            By:  /s/
                                               ---------------------------------
                                               Timothy B. Anderson
                                               Senior Vice President, Corporate
                                               Strategy and Development

                                         NEXELL OF CALIFORNIA, INC.

                                            By:  /s/
                                               ---------------------------------
                                               William A. Albright, Jr.
                                               President<PAGE>

                                                                   EXHIBIT 10.95

                            EMPLOYEE LEASE AGREEMENT

                  THIS EMPLOYEE LEASE AGREEMENT (this "Agreement") dated as of
                                                       ---------
August 31, 2001, by and between Baxter Healthcare Corporation, a Delaware
corporation ("Buyer"), and Nexell of California, Inc., a Delaware corporation,
              -----
and Nexell Therapeutics Inc., a Delaware corporation (collectively, "Sellers").
                                                                     -------

                  WHEREAS, Buyer and Sellers have entered into an Asset Purchase
Agreement, dated as of August 3, 2001 (the "Asset Purchase Agreement"), whereby
                                            ------------------------
Buyer has purchased from Sellers certain of Sellers' assets;

                  WHEREAS, Buyer shall lease from Sellers the services of the
persons listed in Annex A hereto (the "Transition Employees") during the period
                  -------              --------------------
commencing on the date hereof and ending at 11:59 p.m. on the date that is at
the end of the duration of employment listed for each Transition Employee on
Annex A, unless otherwise extended pursuant to this Agreement, or unless Buyer
-------
otherwise provides thirty (30) days written notice that this term is to be
reduced (the "Transition Period");
              -----------------

                  WHEREAS, during the Transition Period, Buyer desires to lease
the services and skills of the Transition Employees from Sellers, and Sellers
desire to maintain the employment of the Transition Employees and to make the
services and skills of such employees available to Buyer hereunder; and

                  WHEREAS, the parties desire to set forth in writing the terms
and conditions pursuant to which this employee leasing arrangement will operate.
This Agreement shall supplement the provisions of the Asset Purchase Agreement.

                  NOW, THEREFORE, in consideration of the promises and mutual
covenants set forth in the Asset Purchase Agreement and herein, and other good
and valuable consideration, the parties hereby agree as follows:

                                   ARTICLE I
                                  DEFINITIONS

                  For the purposes of this Agreement the capitalized terms have
the meanings specified below. Capitalized terms not otherwise defined herein
shall have the meanings ascribed to them in the Asset Purchase Agreement:

                  "Agreement" has the meaning set forth in the preamble hereto.
                   ---------

                  "Asset Purchase Agreement" has the meaning set forth in the
                   ------------------------
first recital hereto.

                  "Buyer" has the meaning set forth in the preamble hereto.
                   -----

                  "COBRA" means the continuation coverage requirements under
                   -----
Code Section 4980B and Part 6 of Title I of ERISA.
<PAGE>

                  "HIPAA" means the Health Insurance Portability and
                   -----
Accountability Act of 1996, as amended.

                  "Lease End Date" means the last day of the Transition Period.
                   --------------

                  "Sellers" has the meaning set forth in the preamble hereto.
                   -------

                  "Seller Plans" means all employee benefit plans and programs
                   ------------
that Sellers generally makes available to their employees.

                  "Transition Employees" has the meaning set forth in the second
                   --------------------
recital hereto.

                  "Transition Period" has the meaning set forth in the second
                   -----------------
recital hereto.

                                  ARTICLE II
                          RESPONSIBILITIES OF SELLERS

                  2.01. Provision of Transition Employees. Subject to the terms
                        ---------------------------------
and conditions hereof, Sellers shall use their reasonable best efforts to
provide to Buyer during the Transition Period the services of the Transition
Employees, to devote their full time and energy to perform the functions and
services that were performed by the Transition Employees in the Toolbox Products
Distribution Business immediately prior to the Transition Period, or such other
functions that Sellers, in consultation with Buyer, may direct.

                  2.02. Status of Transition Employees. All Transition Employees
                        ------------------------------
providing services to Buyer under this Agreement shall at all times during the
Transition Period remain at-will employees of Sellers; provided that Buyer shall
                                                       -------- ----
have the right to request that Sellers remove any Transition Employee as a
service provider to Buyer (at which time any such employee shall cease to be a
Transition Employee); provided, further, that while Sellers shall have the
                      --------  -------
ultimate authority to make all employee-related decisions, they shall make all
reasonable efforts to accommodate Buyer's needs and desires in operating the
Toolbox Products Distribution Business.

                  2.03. Independent Contractor Relationship. (a) Notwithstanding
                        -----------------------------------
any provision hereof to the contrary, nothing herein shall be construed as
giving Buyer primary direction or control over the judgment of a Transition
Employee or the time, location, manner or method in which he or she performs the
services hereunder. The parties stipulate and agree that (i) each Transition
Employee is employed solely by one of the Sellers and not by Buyer, (ii) each
Seller and each Transition Employee is an independent contractor with respect to
his or her duties at Buyer; (iii) this Agreement identifies the work to be
performed by Sellers and its employees, but does not reserve to Buyer primary
direction or control in the time, location, manner or method in which such
services are to be performed; and (iv) Buyer shall not exercise and shall have
no right to designate which services are to be performed by particular
Transition Employees. This Agreement sets forth services to be provided by
Sellers and standards to be satisfied, but does not create the relationship of
an employer and employee as between Buyer and the Transition Employees. All
Transition Employees shall be and remain employees of Sellers and may be
promoted, disciplined, transferred or discharged only by Sellers. Buyer may
consult with Sellers in the discipline of a Transition Employee and may report
any professional,
<PAGE>

technical or other deficiencies in such Transition Employee's performance.

                  (b) Neither Sellers nor Buyer shall represent to any party
that any Transition Employee is an employee of Buyer, or that such Transition
Employee's relationship to Buyer is other than that of an independent
contractor.

                  (c) During the Transition Period, the Transition Employees
shall not participate in any employee benefit plan maintained, sponsored or
contributed to or for the benefit of Buyer employees or be entitled to any
fringe benefits otherwise provided or made available to Buyer's employees.
Moreover, Buyer will not account for any state, local, or federal income taxes,
FICA, employment taxes or other amounts normally withheld from compensation due
to the Transition Employees.

                                  ARTICLE III
                           RESPONSIBILITIES OF BUYER

                  In consideration for the services of the Transition Employees
to be provided pursuant to the terms of this Agreement by Sellers for Buyer,
Buyer shall pay to Sellers, and reimburse them for, the salaries (including
benefits) for the Transition Employees. Notwithstanding anything herein to the
contrary, in no event shall Buyer reimburse Sellers for any severance payments
or other severance compensation or benefits with respect to such Transition
Employees.

                  Payment by Buyer to Sellers of amounts described herein shall
be made within ten (10) business days of the end of each regular pay period,
provided that Sellers have delivered an invoice to Buyer relating thereto at
least five (5) business days prior to the expected date of reimbursement.
Sellers shall send all such statements of account and invoices via overnight
courier to Buyer at the following address: Baxter Healthcare Corporation, Attn.
Cynthia L. Collins, One Baxter Parkway, Deerfield, Illinois 60015. Sellers shall
keep appropriate books and records of account, in reasonable detail, of the
costs submitted to Buyer for reimbursement and shall provide to Buyer
appropriate supporting documentation for any material out-of-pocket and third
party expenses.

                                  ARTICLE IV
                                    PAYROLL

                  Sellers shall be responsible for maintaining payroll for
compensating Transition Employees, fulfilling all payroll tax and benefit
withholding and depositing obligations, and operating and administering all the
Seller Plans. During the Transition Period, Transition Employees shall be paid
through Sellers' payroll at the same rate such Transition Employees were paid as
of the beginning of the Transition Period. Sellers shall not change the salary
of any Transition Employee or pay a bonus to any Transition Employee during the
Transition Period, except as may be requested by Buyer in writing. Pursuant to
the terms of Article III, Buyer shall pay to Sellers or reimburse them for the
amount paid by Sellers with respect to Transition Employees through Sellers'
payroll system during the Transition Period (including payments for compensation
(whether or not deferred), any FICA taxes and employment taxes and unemployment
contributions paid by Sellers to Transition Employees).
<PAGE>

                                   ARTICLE V
                                   BENEFITS

                  5.01. Participation in Sellers' Plans. Effective during the
                        -------------------------------
Transition Period, the Transition Employees shall participate in the Seller
Plans, which shall be operated and administered solely by Sellers.

                  5.02. COBRA and HIPAA. Sellers shall be solely responsible for
                        ---------------
the COBRA administration of Sellers' group health plans in respect of Transition
Employees (and their qualified beneficiaries), including providing the
appropriate COBRA notices and making available any coverage required under COBRA
in respect of such individuals for any qualifying event (as defined in COBRA)
that occurs at any time (whether before, during or after the Transition Period).
Sellers shall provide a timely certificate of creditable coverage (within the
meaning of HIPAA) to each Transition Employee (and his or her covered
dependents) for any HIPAA triggering event which occurs at any time (whether
before, during or after the Transition Period).

                  5.03. Vacation, Etc. During the Transition Period, each
                        -------------
Transition Employee's vacation days, sick leave and all other leaves of absence
shall be (or continue to be) administered in accordance with Sellers' policies
and programs applicable to Sellers' employees.

                  5.04. Workers' Compensation. Sellers shall remain responsible
                        ---------------------
and retain liability for, and shall pay, if and when due before or after the
Closing Date, the expense for all workers' compensation benefits (including
weekly benefits, medical and rehabilitation expenses, and any other expenses or
obligations) payable on account of any injuries, illnesses or other conditions
of Transition Employees that occur at any time (whether before, during or after
the Transition Period).

                                  ARTICLE VI
                          PERFORMANCE AND COOPERATION

                  6.01. Availability of Personnel. (a) Upon the advance request
                        -------------------------
of Buyer setting forth in detail the assistance that is required, Sellers shall
provide reasonably necessary assistance in the rendering of transition services
at a place as the parties from time to time may mutually agree.

                  (b) Notwithstanding anything to the contrary contained herein,
Sellers shall make such persons providing transition services under this
Agreement who are employees of Sellers or any of their Affiliates (other than
the Transition Employees) available at such times and for such periods as are
reasonable to Sellers in light of the fact that these persons are responsible
for Sellers' and its Affiliate's operations.

                  (c) For purposes of this Agreement each party hereby appoints
the person named below as its primary contact for any and all matters
hereunder:
<PAGE>

Sellers:

         President, Nexell of California, Inc.
         Facsimile Number: (949) 470-6645

Buyer:

         Cynthia L. Collins
         General Manager
         Facsimile Number: (847) 948-4684

                  6.02. Delivery of Information; Cooperation Between the
                        ------------------------------------------------
Parties. (a) Buyer shall provide Sellers with such information and materials
-------
reasonably necessary to effect Sellers' prompt and complete performance of their
duties and obligations under this Agreement. The parties agree that they shall
cooperate with each other and shall act in such a manner as to promote the
prompt and efficient completion of the obligations hereunder.

                  (b) Subject to applicable law, upon termination of this
Agreement, Sellers shall provide to Buyer (i) copies of information that relates
to Sellers and the Transition Employees that was provided to Sellers or
generated by Sellers in the course of performing the services described herein,
and (ii) computer backup copies of such information that is not on systems
shared by Sellers and Buyer. Sellers shall maintain computer backup copies of
all such information that is on computer systems for one year from the date that
this Agreement is terminated and shall make available to Buyer upon reasonable
request for one year from the date that this Agreement is terminated computer
backup copies of such information that is not on systems that are shared by
Sellers and Buyer.

                  (c) The terms of this Section shall survive the termination of
this Agreement until the first anniversary of the termination of this Agreement.

                  6.03. Termination. Notwithstanding anything contained herein
                        -----------
to the contrary, this Agreement and the Transition Period may be terminated at
any time as follows:

                  (a) by mutual consent of Buyer and Sellers; or

                  (b) by Buyer in the event of any material breach by Sellers of
any of Sellers' other agreements contained herein.

The party desiring to terminate or extend this Agreement and the Transition
Period shall give written notice pursuant to Section 7.04 to the other party
hereto. The rights and obligations of Buyer and Sellers under this Agreement
shall survive any termination of this Agreement or the Transition Period.

                                  ARTICLE VII
                                 MISCELLANEOUS

                  7.01. Captions. The headings of the several Articles and
                        --------
Sections of this Agreement are inserted for convenience of reference only and do
not constitute a part of this
<PAGE>

Agreement.

                  7.02. Governing Law. This Agreement shall be governed by, and
                        -------------
construed in accordance with, the laws of the State of Delaware, without
reference to or application of any conflicts of laws principles.

                  7.03. Counterparts. This Agreement may be executed in any
                        ------------
number of counterparts, each of which shall be deemed to be an original and all
of which shall constitute one and the same agreement.

                  7.04. Notices. Any notice or communication under this
                        -------
Agreement shall be made in a manner consistent with Section 15.1 of the Asset
Purchase Agreement.

                  7.05. Assignment. This Agreement shall inure to the benefit of
                        ----------
and be binding on the successors, assigns and legal representatives of each of
the parties; provided that no party shall assign this Agreement without the
written consent of the other party except that Buyer may assign, in whole or
from time to time in part, to one or more of its Affiliates, Buyer's rights and
obligations hereunder.

                  7.06. Amendment and Waiver. This Agreement may not be amended,
                        --------------------
modified or any provision waived, except by an instrument in writing signed by
an executive officer of the entity against whom enforcement of the amendment,
modification or waiver is sought. In the event of a change in the Code
provisions applicable to Transition Employees following the date hereof, the
parties hereby agree to modify this Agreement and the arrangements contemplated
hereunder, as mutually agreed to, in order to avoid or correct any such
violation of law. A waiver by a party of the performance of any covenant,
agreement, obligation, condition, representation or warranty will not be
construed as a waiver of any other covenant, agreement, obligation, condition,
representation or warranty. A waiver by any party of the performance of any act
will not constitute a waiver of the performance of any other act or an identical
act required to be performed at a later time.

                  7.07. Expenses. Except as otherwise provided in this
                        --------
Agreement, each party shall pay its own expenses and costs of attorneys,
accountants and consultants incurred in connection with the transactions
contemplated by this Agreement.

                  7.08. Severability. Any provision of this Agreement which is
                        ------------
prohibited or unenforceable in any jurisdiction will, as to such jurisdiction,
be ineffective to the extent of such prohibition or unenforceability without
invalidating the remaining provisions of this Agreement, and any such
prohibition or unenforceability in any jurisdiction will not invalidate or
render unenforceable such provision in any other jurisdiction. To the extent
permitted by law, the parties waive any provision of law which renders any such
provision prohibited or unenforceable in any respect.

                  7.09. No Third Party Beneficiaries. The terms and provisions
                        ----------------------------
of this Agreement are intended solely for the benefit of Sellers, Buyer and
their respective successors and permitted assigns, and it is not the intention
of the parties to confer third-party beneficiary rights upon any other person or
entity. No Transition Employee, beneficiary or dependent of a Transition
Employee or other person shall be regarded for any purpose as a third party
<PAGE>

beneficiary of this Agreement.

                  7.10. Relationship of Parties. Nothing contained herein shall
                        -----------------------
be deemed or construed by Sellers or Buyer or for any other party as creating a
relationship of principal and agent or of partnership or joint venture among the
parties hereto.

                                  * * * * * *
<PAGE>

                  IN WITNESS WHEREOF, the parties hereto have duly executed and
delivered this Agreement as of the date first above written.

                                                BAXTER HEALTHCARE CORPORATION

                                                By:   /s/
                                                   -----------------------------
                                                Name:
                                                Title:

                                                NEXELL OF CALIFORNIA, INC.

                                                By:   /s/
                                                   -----------------------------
                                                Name:   William A. Albright, Jr.
                                                Title:  President

                                                 NEXELL THERAPEUTICS INC.

                                                 By:  /s/
                                                    ----------------------------
                                                 Name:  William A. Albright, Jr.
                                                 Title: President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00029-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00029-of-00352.parquet"}]]